BeStock  
Stocks › Biotechnology › TVTX

Travere Therapeutic TVTX

US equityMarket cap rank #2128Biotechnology
$47.00 −$1.30 (-2.69%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $47.29 +0.62%
Open$48.09
Prev close$48.30
Day range$46.90 – $49.35
Volume1.33M
Market cap$4.51B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership114.6%-1.31 pts vs. prior quarter
Institutions holding420+22 vs. prior quarter
Insider trades (recent)18 buys / 32 sellsNet selling
Short interest10.14% of floatDays to cover 4.7 · as of 30 Oct 2026
Short-sale volume share25.3%5-day average of daily volume

Short-sale volume as % of daily volume

7%17%27%37%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.71M (12 inflow days, 8 outflow days).

Net flow by order size, last 20 sessions

−$8.2MSuper+$6.5MBig+$2.3MMid+$8.7MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 35.1% of shares outstanding.

Largest holders

  • Janus Henderson Group plc11.80%
  • BlackRock9.04%
  • FMR5.35%
  • State Street Global Advisors4.57%
  • Vanguard Capital Management, LLC4.37%
  • Bank of America Corporation4.09%
  • Perceptive Advisors LLC3.91%
  • Vanguard Portfolio Management, LLC3.17%

By investor type

  • Mutual Fund77.26%
  • Hedge Fund19.66%
  • Public Company6.92%
  • VC/PE Fund5.70%
  • Private Company2.89%
  • Individual/Insider1.08%
  • Insurance Company0.88%
  • Government Pension Fund0.69%

Reported short interest has fallen from 12.67% to 10.14% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +1,498,541 3.2%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +718,109 1.2%
BlackRock Mutual Fund 2026/Q3 +652,568 9.0%
Russell Investment Management, LLC Mutual Fund 2026/Q3 +382,371 0.8%
Barclays PLC Public Company 2026/Q3 +327,622 0.4%
Dimensional Fund Advisors Mutual Fund 2026/Q3 +285,823 0.4%
Bank of America Corporation Public Company 2026/Q3 +3,257,423 4.1%
Adage Capital Management, L.P. Hedge Fund 2026/Q3 +1,592,356 2.7%
Marshall Wace LLP Hedge Fund 2026/Q3 +1,154,671 1.4%
BNP Paribas Financial Markets SNC Private Company 2026/Q3 +1,047,578 1.2%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +974,600 2.0%
Strategic Advisers LLC Mutual Fund 2026/Q3 +955,114 1.0%
Qube Research & Technologies Ltd Mutual Fund 2026/Q3 +774,071 1.5%
Rock Springs Capital Management LP Hedge Fund 2026/Q3 +701,115 2.3%
Jane Street Group, LLC Private Company 2026/Q3 +636,419 1.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
14 Oct 2026 Eric Dube Chief Executive Officer Intent to Sell (Form 144) -243,735 $53.27 –
14 Oct 2026 Eric Dube Chief Executive Officer Derivative Exercise and Sale -243,735 $55.02 152,367
16 Sep 2026 Eric Dube Chief Executive Officer Intent to Sell (Form 144) -108,493 $63.48 –
16 Sep 2026 Peter Heerma Chief Commercial Officer Intent to Sell (Form 144) -8,282 $63.48 –
16 Sep 2026 Eric Dube Chief Executive Officer Derivative Exercise and Sale -400,000 $65.31 152,367
16 Sep 2026 Peter Heerma Chief Commercial Officer Derivative Exercise and Sale -258,189 $65.07 61,430
15 Sep 2026 William Rote Chief Research Officer Intent to Sell (Form 144) -112,850 $62.51 –
15 Sep 2026 Eric Dube Chief Executive Officer Intent to Sell (Form 144) -195,841 $62.51 –
15 Sep 2026 Peter Heerma Chief Commercial Officer Intent to Sell (Form 144) -172,717 $62.51 –
14 Sep 2026 Elizabeth Reed Chief Legal Officer, General Counsel & Secretary Derivative Exercise and Sale -37,500 $65.31 105,389
14 Sep 2026 William Rote Chief Research Officer Intent to Sell (Form 144) -96,198 $65.79 –
14 Sep 2026 Christopher Cline Chief Financial Officer Automatic Disposition -30,508 $65.31 87,508
14 Sep 2026 Christopher Cline Chief Financial Officer Derivative Exercise and Sale -20,000 $62.00 87,508
14 Sep 2026 Eric Dube Chief Executive Officer Intent to Sell (Form 144) -95,666 $65.79 –
14 Sep 2026 Peter Heerma Chief Commercial Officer Automatic Disposition -25,000 $65.31 61,430
14 Sep 2026 Sandra Calvin SVP & Chief Accounting Officer Derivative Exercise and Sale -5,375 $63.66 42,353
14 Sep 2026 Jula Inrig Executive VP, Head of Research & Development and Chief Medical Officer Automatic Disposition -12,279 $65.31 100,491
14 Sep 2026 Jula Inrig Executive VP, Head of Research & Development and Chief Medical Officer Derivative Exercise and Sale -32,395 $62.62 100,491
9 Sep 2026 Jeffrey Meckler Independent Director Derivative Exercise and Sale -20,000 $68.09 91,500
1 Sep 2026 Christopher Cline Chief Financial Officer Open Market Disposition -642 $66.37 118,016

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 9,561,082 10.1% 4.7
15 Oct 2026 10,913,583 11.6% 5.2
30 Sep 2026 12,655,839 13.4% 7.2
15 Sep 2026 12,955,933 13.7% 10.4
31 Aug 2026 12,004,820 12.7% 9.6
14 Aug 2026 11,943,638 12.7% 5.7

Discussion

No comments yet — be the first to weigh in on TVTX.

Sign in to join the discussion.

Scroll to Top